In vitro and in vivo analysis of metabolites involved in the TCA cycle and glutamine metabolism associated with cisplatin resistance in human lung cancer

References

• Liu T, Peng F, Yu J, et al. LC-MS-based lipid profile in colorectal cancer patients: tAGs are the main disturbed lipid markers of colorectal cancer progression. Anal Bioanal Chem. 2019;411(20):5079–5088.
   PubMed Web of Science ®Google Scholar
• Chen P, Cai L, Huffman K, et al. Metabolic diversity in human non-small cell lung cancer cells. Mol Cell. 2019;76(5):838–851.
   PubMed Web of Science ®Google Scholar
• Bott AJ, Shen J, Tonelli C, et al. Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism. Cell Rep. 2019;29(5):1287–1298.
   PubMed Web of Science ®Google Scholar
• Hudson CD, Savadelis A, Nagaraj AB, et al. Altered glutamine metabolism in platinum resistant ovarian cancer. Oncotarget. 2016;7(27):41637–41649.
   PubMedGoogle Scholar
• Masamha CP, LaFontaine P. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy. J Cell Biochem. 2018;119(7):6136–6145.
   PubMed Web of Science ®Google Scholar
• Obrist F, Michels J, Durand S et al.. Metabolic vulnerability of cisplatin‐resistant cancers. The EMBO journal, 37(14), n/a-n/a (2018)
   Google Scholar
• Anderson NM, Mucka P, Kern JG, et al. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9(2):216–237.
   PubMed Web of Science ®Google Scholar
• Tardito S, Oudin A, Ahmed SU, et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol. 2015;17(12):1556–1568.
   PubMed Web of Science ®Google Scholar
• Cluntun AA, Lukey MJ, Cerione RA, et al. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer. 2017;3(3):169–180.
   PubMed Web of Science ®Google Scholar
• Peng F, Liu Y, He C, et al. Prediction of platinum-based chemotherapy efficacy in lung cancer based on LC–MS metabolomics approach. J Pharmaceut Biomed. 2018;154(95):95–101.
   Google Scholar
• Ghassempour A, Nojavan S, Talebpour Z, et al. Monitoring of the fermentation media of citric acid by the trimethylsilyl derivatives of the organic acids formed. J Agr Food Chem. 2004;52(21):6384–6388.
   PubMed Web of Science ®Google Scholar
• Han J, Gagnon S, Eckle T, et al. Metabolomic analysis of key central carbon metabolism carboxylic acids as their 3-nitrophenylhydrazones by UPLC/ESI-MS. ELECTROPHORESIS. 2013;34(19):2891–2900.
   PubMed Web of Science ®Google Scholar
• Han J, Lin K, Sequeira C, et al. An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography–tandem mass spectrometry. Anal Chim Acta. 2015;854(86–94):86–94.
   PubMedGoogle Scholar
• Kowal S, Balsaa P, Werres F, et al. Fully automated standard addition method for the quantification of 29 polar pesticide metabolites in different water bodies using LC-MS/MS. Anal Bioanal Chem. 2013;405(19):6337–6351.
   PubMed Web of Science ®Google Scholar
• Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334–343.
   PubMed Web of Science ®Google Scholar
• Muthu M, Kumar R, Syed Khaja AS, et al. GLUL ablation can confer drug resistance to cancer cells via a malate-aspartate shuttle-mediated mechanism. Cancers (Basel). 2019;11(12):1945.
   Web of Science ®Google Scholar
• Stäubert C, Bhuiyan H, Lindahl A, et al. Rewired metabolism in drug-resistant leukemia cells. J Biol Chem. 2015;290(13):8348–8359.
   PubMed Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with npm1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology. 2010;28(22):3636–3643.
   PubMed Web of Science ®Google Scholar
• Wise DR, Ward PS, Shay JES, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of -ketoglutarate to citrate to support cell growth and viability. Proc Nat Acad Sci. 2011;108(49):19611–19616.
   PubMed Web of Science ®Google Scholar
• Le A, Lane AN, Hamaker M, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012;15(1):110–121.
   PubMed Web of Science ®Google Scholar
• Terunuma A, Putluri N, Mishra P, et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014;124(1):398–412.
   PubMed Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell. 2010;17(3):225–234.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12(5):463–469.
   PubMed Web of Science ®Google Scholar
• Sulkowski PL, Corso CD, Robinson ND, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375):eaal2463.
   PubMed Web of Science ®Google Scholar
• Khurshed M, Aarnoudse N, Hulsbos R, et al. IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity. Faseb J. 2018;j201800547R.
   Web of Science ®Google Scholar